

	DISCOVERY			TRANSLATION			DEVELOPMENT		IMPLEMENTATION
	Screen	Hit-to-lead	Lead optimization	Pre-clinical	Phase I	Phase IIa/ Proof-of-concept	Phase IIb/III	Registration	Treatment access
<b>SLEEPING SICKNESS</b>			SCYX-1330682 + SCYX-1608210				Acoziborole + Fexinidazole for <i>T.b. rhodesiense</i> +		Fexinidazole for <i>T.b.gambiense</i> * + Nifurtimox-eflornithine combination therapy (NECT)*
<b>LEISHMANIASIS</b>	Screening	Leishmaniasis Hit-to-lead	S07 series +	DNDI-6174 +	DNDI-6148 + DNDI-0690 + GSK899 DDD853651 + Novartis LXE408 + CpG-D35 for CL + GSK245 DDD1305143 +		New CL combination New treatments for PKDL Miltefosine + paromomycin combination (Africa)	New VL treatments (Latin America) New treatments for HIV/VL	SSG&PM (East Africa)* New VL treatments (South Asia)*
		NTD Drug Discovery Booster Hit-to-lead	CF series +						
		Chagas disease Hit-to-lead	Oxaborole profiling +	Biomarkers		Fexinidazole +	New benznidazole regimens +		Benznidazole paediatric dosage forms*
		NTD Drug Discovery Booster Hit-to-lead	UW series +						
			Daiichi Sankyo series +						
					CC6166 +	Oxfendazole +	Emodepside + TylAMac (ABBV-4083) +		
<b>FILARIA: RIVER BLINDNESS</b>									
<b>MYCETOMA</b>							Fosravuconazole +		
<b>HIV</b>					5 FC (cryptococcal meningitis)			4-in-1 (ABC/3TC/LPV/r)	Super-booster therapy for children with HIV/TB* 2-in-1 LPV/r pellets and ABC/3TC or AZT/3TC
<b>HEPATITIS C</b>							Ravidasvir + sofosbuvir +	Ravidasvir +	
<b>COVID 19</b>		Hit-to-Lead broad-spectrum antivirals		Preclinical support			ANTICOV		
<b>MALARIA</b> ★									Fixed-dose combination ASMQ* Fixed-dose combination ASAQ*

★ Implementation transferred to the Medicines for Malaria Venture in 2015

+ NCE (New chemical entity)

\* Treatments delivered by DNDi